Phathom Pharmaceuticals (NASDAQ:PHAT) versus Scinai Immunotherapeutics (NASDAQ:SCNI) Head to Head Survey

Scinai Immunotherapeutics (NASDAQ:SCNI) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Scinai Immunotherapeutics and Phathom Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scinai Immunotherapeutics	1	0	0	0	1.00
Phathom Pharmaceuticals	1	2	5	1	2.67

Phathom Pharmaceuticals has a consensus price target of $21.00, suggesting a potential upside of 51.73%. Given Phathom Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Phathom Pharmaceuticals is more favorable than Scinai Immunotherapeutics.

Institutional & Insider Ownership

58.4% of Scinai Immunotherapeutics shares are held by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are held by institutional investors. 6.0% of Scinai Immunotherapeutics shares are held by insiders. Comparatively, 24.1% of Phathom Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Risk and Volatility

Scinai Immunotherapeutics has a beta of 1.72, suggesting that its stock price is 72% more volatile than the S&P 500. Comparatively, Phathom Pharmaceuticals has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500.

Valuation & Earnings

This table compares Scinai Immunotherapeutics and Phathom Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scinai Immunotherapeutics	$660,000.00	4.98	$4.80 million	($9.57)	-0.11
Phathom Pharmaceuticals	$55.25 million	17.89	-$334.33 million	($3.82)	-3.62

Scinai Immunotherapeutics has higher earnings, but lower revenue than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Scinai Immunotherapeutics and Phathom Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Scinai Immunotherapeutics	N/A	N/A	N/A
Phathom Pharmaceuticals	-186.53%	N/A	-79.41%

Summary

Phathom Pharmaceuticals beats Scinai Immunotherapeutics on 9 of the 14 factors compared between the two stocks.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.